Philadelphia Trust Co. Has $3.85 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Philadelphia Trust Co. cut its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 9.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 318,230 shares of the company's stock after selling 34,132 shares during the quarter. Philadelphia Trust Co. owned approximately 0.06% of Elanco Animal Health worth $3,854,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ELAN. Steward Partners Investment Advisory LLC boosted its position in Elanco Animal Health by 28.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after purchasing an additional 2,264 shares during the period. DDD Partners LLC bought a new position in Elanco Animal Health in the 4th quarter valued at about $5,974,000. Geode Capital Management LLC boosted its holdings in shares of Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company's stock worth $115,623,000 after acquiring an additional 65,303 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of Elanco Animal Health by 24.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after purchasing an additional 209,734 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Elanco Animal Health by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock worth $5,349,000 after purchasing an additional 45,795 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ELAN shares. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley cut their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Piper Sandler lowered their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Stifel Nicolaus cut their price target on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a research note on Monday. Finally, UBS Group lowered their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Elanco Animal Health has an average rating of "Hold" and a consensus target price of $14.67.

Elanco Animal Health Price Performance

NYSE:ELAN traded up $0.27 on Thursday, hitting $8.37. The company had a trading volume of 2,107,913 shares, compared to its average volume of 4,898,911. The firm has a 50 day moving average of $10.38 and a two-hundred day moving average of $11.93. The stock has a market capitalization of $4.15 billion, a price-to-earnings ratio of 20.91, a PEG ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 52 week low of $8.03 and a 52 week high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company's revenue was down 1.4% compared to the same quarter last year. During the same period last year, the business earned $0.08 EPS. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 0.57% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.